June 17, 2021 -- Biopharmaceutical company Kite announced a partnership with Shoreline Biosciences to develop novel cell therapies across a variety of cancer targets.
Kite, a Gilead Sciences company based in Santa Monica, CA, specializes in extensive cell therapy development and commercialization and manufacturing. Shoreline is developing a pipeline of natural killer cell and macrophage cell therapy candidates based on induced pluripotent stem cell (iPSC) differentiation methods and genetic reprogramming of pathways relevant to diseases.
Shoreline will receive an undisclosed upfront payment and will be eligible to receive additional payments totaling over $2.3 billion, as well as royalties based on achievement of certain development and commercial milestones, the companies said.
Copyright © 2021 scienceboard.net